Edition:
United States

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

104.40GBp
5:44am EDT
Change (% chg)

0.20 (+0.19%)
Prev Close
104.20
Open
103.50
Day's High
106.10
Day's Low
103.10
Volume
509,544
Avg. Vol
2,082,514
52-wk High
166.97
52-wk Low
88.90

Chart for

About

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) -... (more)

Overall

Beta: 0.44
Market Cap(Mil.): £707.88
Shares Outstanding(Mil.): 679.34
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.51 16.21
EPS (TTM): -- -- --
ROI: -- 15.10 14.56
ROE: -- 16.34 13.83

BRIEF-Vectura Group posts HY revenue of 78.8 million pounds

* HY REVENUE 78.8 MILLION POUNDS VERSUS 73.9 MILLION POUNDS A YEAR AGO

Sep 06 2017

BRIEF-Vectura signs VR410 agreement with Pulmatrix

* PROGRESSING DEVELOPMENT OF BRANDED GENERIC TIOTROPIUM BROMIDE PROGRAMME (VR410) FOR US MARKET, ACCELERATED THROUGH LICENCE DEAL WITH PULMATRIX

Sep 06 2017

BRIEF-Vectura announces ANDA filing for US generic version of Advair Diskus

* CONFIRMS STATEMENT MADE BY PARTNER HIKMA IN RESPECT OF ANDA FILING FOR A US GENERIC VERSION OF ADVAIR DISKUS SOURCE TEXT FOR EIKON: FURTHER COMPANY COVERAGE:

Aug 17 2017

Vectura signs deal with Novartis for generic U.S. lung therapy

Vectura Group Plc said on Wednesday it has signed an exclusive deal with Sandoz AG, a unit of Swiss drugmaker Novartis, to develop a generic copy of an existing combined lung therapy for the U.S. market.

Jun 28 2017

Vectura signs deal with Novartis for generic U.S. lung therapy

June 28 Vectura Group Plc said on Wednesday it has signed an exclusive deal with Sandoz AG, a unit of Swiss drugmaker Novartis, to develop a generic copy of an existing combined lung therapy for the U.S. market.

Jun 28 2017

BRIEF-Vectura inks new U.S. deals for generic asthma therapy​

* ‍New development and licence agreement for a U.S. inhaled generic​

Jun 28 2017

BRIEF-Vectura says to present positive phase I data for VR942

* Vectura group plc - vr942 positive phase i data to be presented at American Thoracic Society 113th Annual Conference

May 22 2017

BRIEF-Vectura posts 9-month loss before taxation of 40.1 million stg

* Nine-Month pretax loss 40.1 million stg versus loss of 1.9 million stg for 12 months ended March 31, 2016

Mar 21 2017

Earnings vs. Estimates